On Friday, Shares of Marriott International Inc (NASDAQ:MAR), lost -2.05% to $75.29.
Acclaimed time-lapse photographer Paul Richardson has perfectly captured the urban buzz of both London and Paris in a pair of new hyperlapse videos, which were created in partnership with Marriott International, to give a real view of the vibrant culture and flow of both cities.
The project showcases the atmosphere of Europe’s most popular capital cities in a way static imagery and typical short-form videos cannot. Each clip is 1:20 long and comprises over 30,000 animated photographs, taking viewers on a whirlwind journey to such recognisable sights as Buckingham Palace, the London Eye, Piccadilly Circus, the Eiffel Tower, Sacré-Cœur and more.
“Our aim was to reveal the heart of both of these capitals and stir up a natural sense of wanderlust in viewers,” said Frederic Schaub, Global Sites SEO Manager for Marriott International. “We wanted people to get a feel for each city in just over a minute, by showing points of view from the rooftops of some of our hotels in these two beautiful destinations.”
Marriott International, Inc. is a diversified global lodging company. The Company is an operator, franchisor and licensor of hotels and timeshare properties across the world. It also operates markets and develops residential properties and provides services to home/condominium owner associations. It has three segments: North American Full-Service, North American Limited-Service and International.
Shares of Maxim Integrated Products Inc. (NASDAQ:MXIM), declined -2.99% to $37.95, during its last trading session.
Maxim Integrated Products, stated net revenue of $563 million for its first quarter of fiscal 2016 ended September 26, 2015, a 3% decrease from the $583 million revenue recorded in the preceding quarter, and a 3% decrease from the same quarter of last year.
Tunc Doluca, President and Chief Executive Officer, commented, “Our first quarter financial performance was in line with our expectations.” Mr. Doluca continued, “Our soft outlook for the December quarter reflects an unusually high decline in Consumer revenue due to product cycle timing, continued weakness in communications infrastructure, and a seasonally down industrial market. Looking ahead to the March quarter, we expect a rebound of our business, driven by product cycles in Consumer, and continued momentum and visibility in Automotive. We are also on track to reduce costs by $180 million annually. ”
Maxim Integrated Products, Inc. is engaged in designing, developing, manufacturing and marketing a range of linear and mixed-signal integrated circuits, referred to as analog circuits. The Company also provides a range of high-frequency process technologies and capabilities for use in custom designs. The Company’s products comprise switching regulators, charge pumps, linear regulators, light-emitting diode drivers, power switching, transceivers, level translators, broadband switches, current loop products, real-time clocks, data loggers and microcontrollers.
Finally, Shares of Baxalta Inc (NYSE:BXLT), ended its last trade with 6.54% gain, and closed at $33.41.
Baxalta Incorporated, declared that Health Canada has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in patients with attained hemophilia A caused by autoantibodies to coagulation Factor VIII (FVIII), a very rare and life-threatening acute bleeding disorder. OBIZUR is the first recombinant porcine sequence FVIII treatment available for patients with attained hemophilia A, specifically designed to enable physicians to monitor treatment response by measuring FVIII activity levels in addition to clinical assessments.
“The approval of OBIZUR in Canada provides physicians with an important new and effective treatment for attained hemophilia A,” said Dr. Jean St-Louis, hematologist at Hôpital Maisonneuve-Rosemont and associate professor at Université de Montréal. “This is a very challenging condition to treat and as an investigator in the clinical study, I had the opportunity to see the positive impact that OBIZUR can have for patients and their treating team.”
The approval is supported by the positive results of a global, prospective, controlled, multi-center Phase II/III open-label clinical trial that examined the efficacy of OBIZUR in the treatment of serious bleeding episodes in patients with attained hemophilia A. All patients treated with OBIZUR, 100 percent (28/28), showed a positive response and clinical improvement at 24 hours after the initial infusion. Successful control (resolution) of the initial bleeding episode was observed in 86 percent (24/28) of all patients and in 94 percent (16/17) of those treated with OBIZUR as the first-line treatment. The development of antibodies to porcine FVIII was the only adverse reaction stated in more than five percent of patients.
Baxalta Incorporated is a biopharmaceutical company. The Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. The Company also focuses on disease areas, counting oncology, in addition to technology platforms, counting gene therapy and biosimilars.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.